Navigation Links
EntreMed Reports Second Quarter 2012 Financial Results
Date:8/14/2012

ROCKVILLE, Md., Aug. 14, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and six-month periods ending June 30, 2012. 

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO )

EntreMed reported a net loss for the second quarter of 2012 of ($10.5 million), or ($0.56) per share. This compares with a net loss of ($1.7 million), or ($0.17) per share, for the same period last year.
For the first six months of 2012 the reported net loss was ($13.0 million), or ($0.86) per share as compared to ($4.3 million), or ($0.41) per share for 2011.  The 2012 net loss amounts included non-cash interest charges associated with our Strategic Financing totaling $9.2 million and $10.0 million for the three and six months ended June 30, 2012, respectively.  Excluding the non-cash interest, net loss for the second quarter and first six months of 2012 was ($1.3 million), or ($0.07) per share and ($3.0 million) or ($0.19) per share, respectively.

As of June 30, 2012, EntreMed had cash and cash equivalents of approximately $10.1 million.

Sara B. Capitelli, EntreMed's Vice President, Finance & Principal Accounting Officer, commented on the second quarter results, "Our second quarter 2012 financial results were in line with expectations.  Our research and development expenses for the second quarter decreased compared to the previous year as we completed enrollment of patients in the ENMD-2076 Phase 2 ovarian cancer study in 2011.  We anticipate third and fourth quarter operating expenses to increase as we execute on our clinical development plan in the US and China."

Ken Ren, PhD, EntreMed's Chief Executive Officer, further comme
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
2. EntreMed Reports First Quarter 2012 Financial Results
3. Nile Therapeutics Reports 2012 Second Quarter Financial Results
4. PDI Reports 2012 Second Quarter Financial Results
5. Neuland Labs Reports First Quarter Fiscal Year 2013 Financial Results
6. Patient Safety Technologies Reports Second Quarter 2012 Results
7. Soligenix Reports Second Quarter 2012 Financial Results and Highlights Recent Accomplishments
8. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
9. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
10. AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
11. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Inc. (NYSE: MTD ) today announced second ... , Sales in local currency increased by ... Reported sales increased 5% which included a 1% benefit ... as reported (EPS) were $2.49, compared with $2.24 in ... an increase of 9% over the prior-year amount of ...
(Date:7/24/2014)... July 24, 2014 Omnicell, Inc. (NASDAQ: ... medication and supply management solutions and analytics software ... July 31, to discuss the Company,s Second Quarter ... Quarter 2014 earnings conference call and webcastWhen: ... Randall Lipps, chairman, president and chief executive officer ...
(Date:7/24/2014)... VANCOUVER, British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today ... the company,s fiscal year from December 31 to June 30. ... before September 30, 2014. Jeffrey Bacha , ... year end is an important step in achieving our goal ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3
... 28, 2011 Volcano Corporation (NASDAQ: VOLC ... therapy tools designed to enhance the treatment of coronary ... Leslie V. Norwalk, Esq., and Eric J. Topol, M.D., ... Ms. Norwalk currently serves as strategic counsel to EpsteinBeckerGreen, ...
... -- China Biologic Products, Inc. (Nasdaq: CBPO, "China Biologic" or ... the People,s Republic of China, today announced that it has ... Awards in the category of "Best Company in an Emerging ... on November 3, 2011 at the Grosvenor House hotel in ...
Cached Medicine Technology:Volcano Corporation Appoints Leslie V. Norwalk and Dr. Eric J. Topol to Board of Directors 2Volcano Corporation Appoints Leslie V. Norwalk and Dr. Eric J. Topol to Board of Directors 3China Biologic Nominated for the 2011 Scrip Award as Best Company in an Emerging Market 2China Biologic Nominated for the 2011 Scrip Award as Best Company in an Emerging Market 3
(Date:7/25/2014)... July 26, 2014 PersonalInjurySolicitorsIreland, a ... help to people who have suffered from a ... of both their new company, and a website, ... the new website explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims , the ... focus of the company is always on the ...
(Date:7/25/2014)... 25, 2014 American motor vehicle owners ... collisions can pay higher premiums for vehicle insurance on ... insurer network to provide SR22 insurance for high risk ... The different coverage network of local agencies providing direct ... search platform now publicly available for any car owner ...
(Date:7/25/2014)... 2014 Consuming too much salt? Overloaded ... , Read the labels! , Learn to decipher the ... relates to health during a "Healthy Eating for You: ... Humility House, 755 Ohltown Road, Austintown. , Registered dietician ... discussion and answer questions. , The presentation is ...
(Date:7/25/2014)... Island (PRWEB) July 25, 2014 Reproductive ... to announce that Dr. Kerri Luzzo, Lead Physician at ... Award" for her professional accomplishments in fertility care and ... , At the 10th Annual PBN Awards ceremony held ... Island, 40 of the most highly regarded, emerging leaders ...
(Date:7/25/2014)... US (PRWEB) July 25, 2014 ... provider of technology-enabled services for the financial, legal, ... its virtual data room business, Merrill DataSite, has ... Year” presented by GrowthBusiness at the M&A Awards ... recognize the achievements of entrepreneurs, management teams, advisors ...
Breaking Medicine News(10 mins):Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2Health News:Learn to Decipher Food Labels at Humility House 2Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2
... interaction with cyclosporine could lead to fatal complications ... People taking the immunosuppressant cyclosporine should avoid consuming ... and possibly lead to deadly consequences, new research ... rats taking cyclosporine -- commonly used to help ...
... 25 NeuroVasx, Inc., a medical device company that ... stroke, announced today that it has received CE Mark ... is a minimally invasive device for the embolization of ... of an artery in the brain. If ruptured, aneurysms ...
... to Assist Processing Plants.SHREVEPORT, La., March 25 Since ... proven to be effective on the poultry processing line ... Salmonella, E. coli , and Listeria . ... help control Campylobacter by pre-screening birds for their current ...
... The 2008 Frost & Sullivan European ... is presented to Ferring Pharmaceuticals. The award ... providing no-needle injection for human growth hormone ... and ZOMAJET VISION X, innovative no-needle delivery ...
... March 25 /PRNewswire-Asia-FirstCall/ -- China Medical,Technologies, Inc. ... a leading China-based,medical device company that develops, ... announced that the Company received,quality testing certificate ... ,SPR System,) from one of the State ...
... March 25 Curemark, LLC, a drug research and ... announced today that the U.S. Food and Drug Administration ... application to initiate its pivotal Phase III clinical trial ... to begin Phase III clinical trials at multiple sites ...
Cached Medicine News:Health News:Licorice May Block Absorption of Organ Transplant Drug 2Health News:NeuroVasx Receives CE Mark for cPAX Aneurysm Treatment System 2Health News:SteriFx Inc. Provides 'Solutions' to Combat Campylobacter 2Health News:Frost & Sullivan Accolade for Ferring Pharmaceuticals 2Health News:Frost & Sullivan Accolade for Ferring Pharmaceuticals 3Health News:China Medical Technologies Announces Receipt of SFDA Quality Testing Certificate for its SPR-based Analysis System 2Health News:Curemark Receives Investigational New Drug Clearance for CM-AT for Autism 2Health News:Curemark Receives Investigational New Drug Clearance for CM-AT for Autism 3
... 45° Prism are designed for ... recommended for tractional retinal detachments ... retinal detachment. They can be ... other midperipheral laser applications. Direct ...
... The 45° Prism ... fundus pathologies and are ... detachments (PDR, BRVO etc.) ... They can be used ...
... The Chalam 15° Prism are ... and are recommended for tractional ... and Rhegmatogenus retinal detachment. They ... photocoagulation and other midperipheral laser ...
The Mid Field lens can be used for air/gas exchange and has a bi-concave design to provide the widest field available in a direct image surgical lens....
Medicine Products: